Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 523

1.

Recurrence and Occurrence of Kaposi's Sarcoma in Patients Living With Human Immunodeficiency Virus (HIV) and on Antiretroviral Therapy, Despite Suppressed HIV Viremia.

Palich R, Veyri M, Valantin MA, Marcelin AG, Guihot A, Pourcher V, Jary A, Solas C, Makinson A, Poizot-Martin I, Costagliola D, Spano JP, Katlama C; CancerVIH Study Group.

Clin Infect Dis. 2019 Aug 20. pii: ciz762. doi: 10.1093/cid/ciz762. [Epub ahead of print]

PMID:
31626689
2.

In situ BCL2 expression is an independent prognostic factor in HIV-associated DLBCL, a LYMPHOVIR cohort study.

Philippe L, Lancar R, Laurent C, Algarte-Genin M, Chassagne-Clément C, Fabiani B, Pierre Chenard M, Lazure T, Parrens M, Charlotte F, Delattre C, Gibault L, Capron F, Goubin-Versini I, Petitjean B, Boué F, Mounier N, Costello R, Costagliola D, Prevot S, Besson C; ANRS-CO16 LYMPHOVIR Cohort.

Br J Haematol. 2019 Aug 29. doi: 10.1111/bjh.16176. [Epub ahead of print]

PMID:
31468517
3.

Estimates of the HIV undiagnosed population in Belgium reveals higher prevalence for MSM with foreign nationality and for geographic areas hosting big cities.

Marty L, Van Beckhoven D, Ost C, Deblonde J, Costagliola D, Sasse A, Supervie V; HERMETIC Study Group.

J Int AIDS Soc. 2019 Aug;22(8):e25371. doi: 10.1002/jia2.25371.

4.

Use of darunavir in HIV-1-infected individuals in routine clinical practice from 2012 to 2016 in France.

Potard V, Canestri A, Gallien S, Costagliola D; French Hospital Database on HIV .

J Antimicrob Chemother. 2019 Nov 1;74(11):3305-3314. doi: 10.1093/jac/dkz338.

PMID:
31384941
5.

Factors influencing the incubation of an infectious form of Creutzfeldt-Jakob disease.

Peckeu L, Brandel JP, Welaratne A, Amar E, Costagliola D, Haïk S.

Clin Infect Dis. 2019 Jul 28. pii: ciz692. doi: 10.1093/cid/ciz692. [Epub ahead of print]

PMID:
31351441
6.

Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study.

Katlama C, Assoumou L, Valantin MA, Soulié C, Martinez E, Béniguel L, Bouchaud O, Raffi F, Molina JM, Fellahi S, Peytavin G, Marcelin AG, Kolta S, Capeau J, Gibowski S, Cardon F, Reynes J, Costagliola D; members of the ANRS 163 ETRAL study .

J Antimicrob Chemother. 2019 Sep 1;74(9):2742-2751. doi: 10.1093/jac/dkz224.

PMID:
31269208
7.

Access to the waiting list and to kidney transplantation for people living with HIV: A national registry study.

Tourret J, Guiguet M, Lassalle M, Grabar S, Lièvre L, Isnard-Bagnis C, Barrou B, Costagliola D, Couchoud C, Abgrall S, Tézenas Du Montcel S.

Am J Transplant. 2019 Jun 17. doi: 10.1111/ajt.15500. [Epub ahead of print]

PMID:
31206243
8.

Pharmacogenetic-Based Interactions between Nutraceuticals and Angiogenesis Inhibitors.

Di Francia R, Berretta M, Benincasa G, D'Avino A, Facchini S, Costagliola D, Rossi P.

Cells. 2019 May 30;8(6). pii: E522. doi: 10.3390/cells8060522. Review.

9.

Brief Report: Impact of ART Classes on the Increasing Risk of Cerebral Small-Vessel Disease in Middle-Aged, Well-Controlled, cART-Treated, HIV-Infected Individuals.

Januel E, Godin O, Moulignier A, Lescure FX, Savatovsky J, Lamirel C, Valin N, Tubiana R, Canestri A, Roux P, Sadik JC, Salomon L, Katlama C, Yazdanpanah Y, Pialoux G, Girard PM, Costagliola D, Assoumou L; Microvascular Brain Retina And Kidney (MicroBREAK) Study Group.

J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):547-551. doi: 10.1097/QAI.0000000000002084.

PMID:
31107300
10.

Prevalence of tubulopathy and association with renal function loss in HIV-infected patients.

Lescure FX, Fellahi S, Pialoux G, Bastard JP, Eme AL, Esteve E, Lebrette MG, Guiard-Schmid JB, Capeau J, Ronco P, Costagliola D, Plaisier E.

Nephrol Dial Transplant. 2019 May 9. pii: gfz081. doi: 10.1093/ndt/gfz081. [Epub ahead of print]

PMID:
31071216
11.

Effect Estimates in Randomized Trials and Observational Studies: Comparing Apples With Apples.

Lodi S, Phillips A, Lundgren J, Logan R, Sharma S, Cole SR, Babiker A, Law M, Chu H, Byrne D, Horban A, Sterne JAC, Porter K, Sabin C, Costagliola D, Abgrall S, Gill J, Touloumi G, Pacheco AG, van Sighem A, Reiss P, Bucher HC, Montoliu Giménez A, Jarrin I, Wittkop L, Meyer L, Perez-Hoyos S, Justice A, Neaton JD, Hernán MA; INSIGHT START Study Group and the HIV-CAUSAL Collaboration.

Am J Epidemiol. 2019 Aug 1;188(8):1569-1577. doi: 10.1093/aje/kwz100.

PMID:
31063192
12.

Epstein-Barr virus biomarkers have no prognostic value in HIV-related Hodgkin lymphoma in the modern combined antiretroviral therapy era.

Lupo J, Germi R, Lancar R, Algarte-Genin M, Hendel-Chavez H, Taoufik Y, Mounier N, Partisani M, Bonnet F, Meyohas MC, Marchou B, Semanova T, Prevot S, Costagliola D, Morand P, Besson C.

AIDS. 2019 May 1;33(6):993-1000. doi: 10.1097/QAD.0000000000002129.

PMID:
30946153
13.

Routine screening for HIV, hepatitis B virus and hepatitis C virus in individuals undergoing oral and maxillofacial surgery.

Assoumou L, Thormann F, Soulié C, Caby F, Dudoit Y, Marcelin AG, Goudot P, Blanc C, Coriat P, Katlama C, Costagliola D, Pourcher V.

HIV Med. 2019 May;20(5):353-358. doi: 10.1111/hiv.12732. Epub 2019 Mar 29.

PMID:
30924598
14.

Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individuals.

Caniglia EC, Robins JM, Cain LE, Sabin C, Logan R, Abgrall S, Mugavero MJ, Hernández-Díaz S, Meyer L, Seng R, Drozd DR, Seage Iii GR, Bonnet F, Le Marec F, Moore RD, Reiss P, van Sighem A, Mathews WC, Jarrín I, Alejos B, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Gill J, Pacheco A, Grinsztejn B, Napravnik S, Jose S, Phillips A, Justice A, Tate J, Bucher HC, Egger M, Furrer H, Miro JM, Casabona J, Porter K, Touloumi G, Crane H, Costagliola D, Saag M, Hernán MA.

Stat Med. 2019 Jun 15;38(13):2428-2446. doi: 10.1002/sim.8120. Epub 2019 Mar 18.

PMID:
30883859
15.

Propensity score analysis of artesunate versus quinine for severe imported Plasmodium falciparum malaria in France.

Elket N, Kendjo E, Thellier M, Assoumou L, Potard V, Taieb A, Tantaoui I, Caumes E, Piarroux R, Roussel C, Buffet P, Costagliola D, Jauréguiberry S; French Artesunate Working Group.

Clin Infect Dis. 2019 Mar 15. pii: ciz206. doi: 10.1093/cid/ciz206. [Epub ahead of print]

PMID:
30874798
16.

Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL Study.

Lê MP, Valantin MA, Assoumou L, Soulie C, Le Mestre S, Weiss L, Yazdanpanah Y, Molina JM, Bouchaud O, Raffi F, Reynes J, Calvez V, Marcelin AG, Costagliola D, Katlama C, Peytavin G; ANRS-163 ETRAL study group.

Pharmacotherapy. 2019 Apr;39(4):514-520. doi: 10.1002/phar.2242. Epub 2019 Apr 1.

PMID:
30815916
17.

Invasive cervical cancer in HIV-infected women: risk and survival relative to those of the general population in France. Results from the French Hospital Database on HIV (FHDH)-Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS) CO4 cohort study.

Grabar S, Hleyhel M, Belot A, Bouvier AM, Tattevin P, Pacanowski J, Genet P, Pradier C, Salmon D, Simon A, Pourcher V, Spano JP, Poizot-Martin I, Costagliola D.

HIV Med. 2019 Mar;20(3):222-229. doi: 10.1111/hiv.12703. Epub 2019 Jan 28.

18.

Low incidence of acute rejection within 6 months of kidney transplantation in HIV-infected recipients treated with raltegravir: the Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS) 153 TREVE trial.

Matignon M, Lelièvre JD, Lahiani A, Abbassi K, Desvaux D, Diallo A, Peraldi MN, Taburet AM, Saillard J, Delaugerre C, Costagliola D, Assoumou L, Grimbert P; ANRS 153 TREVE study group.

HIV Med. 2019 Mar;20(3):202-213. doi: 10.1111/hiv.12700. Epub 2019 Jan 27.

PMID:
30688008
19.

Trends in the risk of myocardial infarction among HIV-1-infected individuals relative to the general population in France: Impact of gender and immune status.

Baldé A, Lang S, Wagner A, Ferrières J, Montaye M, Tattevin P, Cotte L, Aslangul E, Bidégain F, Chéret A, Mary-Krause M, Meynard JL, Molina JM, Partisani M, Roger PM, Boccara F, Costagliola D.

PLoS One. 2019 Jan 16;14(1):e0210253. doi: 10.1371/journal.pone.0210253. eCollection 2019.

20.

Validation and refinement of the clinical staging model in a French cohort of outpatient with schizophrenia (FACE-SZ).

Godin O, Fond G, Bulzacka E, Schürhoff F, Boyer L, Myrtille A, Andrianarisoa M, Aouizerate B, Berna F, Capdevielle D, Chereau I, Dorey JM, Dubertret C, Dubreucq J, Faget C, Lancon C, Leignier S, Mallet J, Misdrahi D, Passerieux C, Rey R, Roux P, Vidailhet P, Costagliola D; FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group, Leboyer M, Llorca PM.

Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jun 8;92:226-234. doi: 10.1016/j.pnpbp.2019.01.003. Epub 2019 Jan 10.

PMID:
30639161
21.

Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.

Lemoine M, Assoumou L, De Wit S, Girard PM, Valantin MA, Katlama C, Necsoi C, Campa P, Huefner AD, Schulze Zur Wiesch J, Rougier H, Bastard JP, Stocker H, Mauss S, Serfaty L, Ratziu V, Menu Y, Schlue J, Behrens G, Bedossa P, Capeau J, Ingiliz P, Costagliola D; ANRS-ECHAM Group.

J Acquir Immune Defic Syndr. 2019 Apr 1;80(4):e86-e94. doi: 10.1097/QAI.0000000000001936.

PMID:
30570529
22.

Determinants of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-1-Positive Individuals With Sustained Virological Suppression on Antiretroviral Therapy.

Gras L, May M, Ryder LP, Trickey A, Helleberg M, Obel N, Thiebaut R, Guest J, Gill J, Crane H, Dias Lima V, dʼArminio Monforte A, Sterling TR, Miro J, Moreno S, Stephan C, Smith C, Tate J, Shepherd L, Saag M, Rieger A, Gillor D, Cavassini M, Montero M, Ingle SM, Reiss P, Costagliola D, Wit FWNM, Sterne J, de Wolf F, Geskus R; Antiretroviral Therapy Cohort Collaboration (ART-CC).

J Acquir Immune Defic Syndr. 2019 Mar 1;80(3):292-300. doi: 10.1097/QAI.0000000000001913.

23.

Impact of Antiretroviral Drugs on Fracture Risk in HIV-Infected Individuals: A Case-Control Study Nested Within the French Hospital Database on HIV (FHDH-ANRS CO4).

Costagliola D, Potard V, Lang S, Abgrall S, Duvivier C, Fischer H, Joly V, Lacombe JM, Valantin MA, Mary-Krause M, Rozenberg S.

J Acquir Immune Defic Syndr. 2019 Feb 1;80(2):214-223. doi: 10.1097/QAI.0000000000001903.

24.

Influence of geographic origin on AIDS and serious non-AIDS morbidity/mortality during cART among heterosexual HIV-infected men and women in France.

de Monteynard LA, Matheron S, Grabar S, de Truchis P, Gilquin J, Pavie J, Launay O, Meynard JL, Khuong-Josses MA, Rey D, Mahamat A, Dray-Spira R, Simon A, Costagliola D, Abgrall S; FHDH-ANRS CO4.

PLoS One. 2018 Oct 31;13(10):e0205385. doi: 10.1371/journal.pone.0205385. eCollection 2018.

25.

CD4+ cell count recovery after combined antiretroviral therapy in the modern combined antiretroviral therapy era.

Roul H, Mary-Krause M, Ghosn J, Delaugerre C, Pialoux G, Cuzin L, Launay O, Lacombe JM, Menard A, De Truchis P, Delfraissy JF, Weiss L, Costagliola D; FHDH-ANRS CO4.

AIDS. 2018 Nov 13;32(17):2605-2614. doi: 10.1097/QAD.0000000000002010.

PMID:
30289817
26.

Are European HIV cohort data within EuroCoord representative of the diagnosed HIV population?

Vourli G, Pharris A, Cazein F, Costagliola D, Dabis F, Del Amo J, Delpech V, Díaz A, Girardi E, Gourlay A, Gunsenheimer-Bartmeyer B, Hernando V, Nikolopoulos G, Porter K, Rosińska M, Sabin C, Suligoi B, Supervie V, Wit F, Touloumi G.

AIDS. 2019 Jan 27;33(1):133-143. doi: 10.1097/QAD.0000000000002034.

27.

Risk factors for loss to follow-up, transfer or death among people living with HIV on their first antiretroviral therapy regimen in Mali.

Baldé A, Lièvre L, Maiga AI, Diallo F, Maiga IA, Costagliola D, Abgrall S.

HIV Med. 2019 Jan;20(1):47-53. doi: 10.1111/hiv.12668. Epub 2018 Sep 30.

PMID:
30270487
28.

Metabolic Syndrome and Illness Severity Predict Relapse at 1-Year Follow-Up in Schizophrenia: The FACE-SZ Cohort.

Godin O, Leboyer M, Schürhoff F, Llorca PM, Boyer L, Andre M, Andrianarisoa M, Aouizerate B, Berna F, Capdevielle D, Chereau I, Dorey JM, Dubertret C, Dubreucq J, Faget C, Lancon C, Leignier S, Mallet J, Misdrahi D, Passerieux C, Rey R, Roux P, Vidailhet P, Costagliola D, Fond G; FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Group.

J Clin Psychiatry. 2018 Sep 18;79(6). pii: 17m12007. doi: 10.4088/JCP.17m12007.

PMID:
30257079
29.

Utility of Epstein-Barr Virus Biomarkers in Human Immunodeficiency Virus-related Lymphomas in the Modern Combined Antiretroviral Therapy Era.

Lupo J, Germi R, Costagliola D, Morand P, Besson C.

Clin Infect Dis. 2019 Feb 15;68(5):891-892. doi: 10.1093/cid/ciy786. No abstract available.

PMID:
30204857
30.

Susceptibility to Creutzfeldt-Jakob disease after human growth hormone treatment in France.

Peckeu L, Brandel JP, Welaratne A, Costagliola D, Haïk S.

Neurology. 2018 Aug 21;91(8):e724-e731. doi: 10.1212/WNL.0000000000006028. Epub 2018 Jul 25.

PMID:
30045957
31.

Impact of etravirine on hospitalization rate between 2005 and 2011 among heavily treated HIV-1-infected individuals on failing regimens.

Potard V, Goujard C, Valantin MA, Lacombe JM, Lahoulou R, Chéret A, Girard PM, Costagliola D; French Hospital Database on HIV (FHDH - ANRS CO4).

BMC Infect Dis. 2018 Jul 11;18(1):326. doi: 10.1186/s12879-018-3231-5.

32.

Long terms trends in CD4+ cell counts, CD8+ cell counts, and the CD4+ :  CD8+ ratio.

Hughes RA, May MT, Tilling K, Taylor N, Wittkop L, Reiss P, Gill J, Schommers P, Costagliola D, Guest JL, Lima VD, d'Arminio Monforte A, Smith C, Cavassini M, Saag M, Castilho JL, Sterne JAC.

AIDS. 2018 Jun 19;32(10):1361-1367. doi: 10.1097/QAD.0000000000001848.

33.

Risk of Progressive Multifocal Leukoencephalopathy in the Combination Antiretroviral Therapy Era in the French Hospital Database on Human Immunodeficiency Virus (ANRS-C4).

Melliez H, Mary-Krause M, Bocket L, Guiguet M, Abgrall S, De Truchis P, Katlama C, Martin-Blondel G, Henn A, Revest M, Robineau O, Khuong-Josses MA, Canestri A, De Castro N, Joly V, Mokhtari S, Risso K, Gasnault J, Costagliola D; French Hospital Database on HIV (ANRS-C4).

Clin Infect Dis. 2018 Jul 2;67(2):275-282. doi: 10.1093/cid/ciy074.

PMID:
29635465
34.

Revealing geographical and population heterogeneity in HIV incidence, undiagnosed HIV prevalence and time to diagnosis to improve prevention and care: estimates for France.

Marty L, Cazein F, Panjo H, Pillonel J, Costagliola D, Supervie V; HERMETIC Study Group.

J Int AIDS Soc. 2018 Mar;21(3):e25100. doi: 10.1002/jia2.25100.

35.

[HIV and cancer : What's new in 2017?]

Gobert A, Veyri M, Poizot-Martin I, Lavolé A, Solas C, Paliche R, Katlama C, Costagliola D, Spano JP.

Bull Cancer. 2018 Mar;105(3):256-262. doi: 10.1016/j.bulcan.2018.02.002. Epub 2018 Mar 13. Review. French.

PMID:
29548534
36.

Silent Cerebral Small-Vessel Disease Is Twice as Prevalent in Middle-Aged Individuals With Well-Controlled, Combination Antiretroviral Therapy-Treated Human Immunodeficiency Virus (HIV) Than in HIV-Uninfected Individuals.

Moulignier A, Savatovsky J, Assoumou L, Lescure FX, Lamirel C, Godin O, Valin N, Tubiana R, Canestri A, Roux P, Sadik JC, Salomon L, Abrivard M, Katlama C, Yazdanpanah Y, Pialoux G, Girard PM, Costagliola D; Microvascular Brain Retina and Kidney (MicroBREAK) Study Group.

Clin Infect Dis. 2018 May 17;66(11):1762-1769. doi: 10.1093/cid/cix1075.

PMID:
29244126
37.

Performance of the marginal structural cox model for estimating individual and joined effects of treatments given in combination.

Lusivika-Nzinga C, Selinger-Leneman H, Grabar S, Costagliola D, Carrat F.

BMC Med Res Methodol. 2017 Dec 4;17(1):160. doi: 10.1186/s12874-017-0434-1.

38.

Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial.

de Truchis P, Assoumou L, Landman R, Mathez D, Le Dû D, Bellet J, Amat K, Katlama C, Gras G, Bouchaud O, Duracinsky M, Abe E, Alvarez JC, Izopet J, Saillard J, Melchior JC, Leibowitch J, Costagliola D, Girard PM, Perronne C; ANRS 162-4D Study Group.

J Antimicrob Chemother. 2018 Mar 1;73(3):738-747. doi: 10.1093/jac/dkx434.

PMID:
29186458
39.

Targeted HIV Screening in Eight Emergency Departments: The DICI-VIH Cluster-Randomized Two-Period Crossover Trial.

Leblanc J, Hejblum G, Costagliola D, Durand-Zaleski I, Lert F, de Truchis P, Verbeke G, Rousseau A, Piquet H, Simon F, Pateron D, Simon T, Crémieux AC; DICI-VIH (Dépistage Infirmier CIblé du VIH) Group.

Ann Emerg Med. 2018 Jul;72(1):41-53.e9. doi: 10.1016/j.annemergmed.2017.09.011. Epub 2017 Oct 31.

PMID:
29092761
40.

CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study.

Wittkop L, Arsandaux J, Trevino A, Schim van der Loeff M, Anderson J, van Sighem A, Böni J, Brun-Vezinet F, Soriano V, Boufassa F, Brockmeyer N, Calmy A, Dabis F, Jarrin I, Dorrucci M, Duque V, Fätkenheuer G, Zangerle R, Ferrer E, Porter K, Judd A, Sipsas NV, Lambotte O, Shepherd L, Leport C, Morrison C, Mussini C, Obel N, Ruelle J, Schwarze-Zander C, Sonnerborg A, Teira R, Torti C, Valadas E, Colin C, Friis-Møller N, Costagliola D, Thiebaut R, Chene G, Matheron S; COHERE in EuroCoord and ACHIeV2e Study Group.

J Antimicrob Chemother. 2017 Oct 1;72(10):2869-2878. doi: 10.1093/jac/dkx210.

41.

Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions.

Caniglia EC, Phillips A, Porter K, Sabin CA, Winston A, Logan R, Gill J, Vandenhende MA, Barger D, Lodi S, Moreno S, Arribas JR, Pacheco A, Cardoso SW, Chrysos G, Gogos C, Abgrall S, Costagliola D, Meyer L, Seng R, van Sighem A, Reiss P, Muga R, Hoyos SP, Braun D, Hauser C, Barrufet P, Leyes M, Tate J, Justice A, Hernán MA.

J Acquir Immune Defic Syndr. 2018 Jan 1;77(1):102-109. doi: 10.1097/QAI.0000000000001562.

42.

Loss of long-term non-progressor and HIV controller status over time in the French Hospital Database on HIV - ANRS CO4.

Grabar S, Selinger-Leneman H, Abgrall S, Pialoux G, Weiss L, Costagliola D.

PLoS One. 2017 Oct 2;12(10):e0184441. doi: 10.1371/journal.pone.0184441. eCollection 2017.

43.

Risk of HIV transmission during combined ART initiation for HIV-infected persons with severe immunosuppression.

Supervie V, Assoumou L, Breban R, Lert F, Costagliola D, Pialoux G, Landman R, Girard PM, Slama L; IMEA 040 DATA Study Group.

J Antimicrob Chemother. 2017 Nov 1;72(11):3172-3176. doi: 10.1093/jac/dkx276.

PMID:
28961977
44.

Outcomes for bipolar patients assessed in the French expert center network: A 2-year follow-up observational study (FondaMental Advanced Centers of Expertise for Bipolar Disorder [FACE-BD]).

Henry C, Godin O, Courtet P, Azorin JM, Gard S, Bellivier F, Polosan M, Kahn JP, Roux P, Aubin V, Costagliola D, Leboyer M, Etain B; FACE-BD collaborators.

Bipolar Disord. 2017 Dec;19(8):651-660. doi: 10.1111/bdi.12539. Epub 2017 Sep 12.

PMID:
28944553
45.

Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era.

Besson C, Lancar R, Prevot S, Algarte-Genin M, Delobel P, Bonnet F, Meyohas MC, Partisani M, Oberic L, Gabarre J, Goujard C, Boue F, Coppo P, Costello R, Hendel-Chavez H, Mekerri N, Dos Santos G, Recher C, Delarue R, Casasnovas RO, Taoufik Y, Mounier N, Costagliola D; ANRS-CO16 LYMPHOVIR Cohort.

AIDS. 2017 Nov 28;31(18):2493-2501. doi: 10.1097/QAD.0000000000001652.

PMID:
28926410
46.

Sleep quality, chronotype and metabolic syndrome components in bipolar disorders during the remission period: Results from the FACE-BD cohort.

Godin O, Henry C, Leboyer M, Azorin JM, Aubin V, Bellivier F, Polosan M, Courtet P, Gard S, Kahn JP, Loftus J, Passerieux C, Costagliola D, Etain B.

Chronobiol Int. 2017;34(8):1114-1124. doi: 10.1080/07420528.2017.1332071. Epub 2017 Sep 14.

PMID:
28910540
47.

CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC).

Trickey A, May MT, Schommers P, Tate J, Ingle SM, Guest JL, Gill MJ, Zangerle R, Saag M, Reiss P, Monforte AD, Johnson M, Lima VD, Sterling TR, Cavassini M, Wittkop L, Costagliola D, Sterne JAC; Antiretroviral Therapy Cohort Collaboration (ART-CC).

Clin Infect Dis. 2017 Sep 15;65(6):959-966. doi: 10.1093/cid/cix466.

48.

Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older.

Lodi S, Costagliola D, Sabin C, Del Amo J, Logan R, Abgrall S, Reiss P, van Sighem A, Jose S, Blanco JR, Hernando V, Bucher HC, Kovari H, Segura F, Ambrosioni J, Gogos CA, Pantazis N, Dabis F, Vandenhende MA, Meyer L, Seng R, Gill MJ, Krentz H, Phillips AN, Porter K, Grinsztejn B, Pacheco AG, Muga R, Tate J, Justice A, Hernán MA.

J Acquir Immune Defic Syndr. 2017 Nov 1;76(3):311-318. doi: 10.1097/QAI.0000000000001498.

49.

Predictors of rapid high weight gain in schizophrenia: Longitudinal analysis of the French FACE-SZ cohort.

Godin O, Leboyer M, Schürhoff F, Boyer L, Andrianarisoa M, Brunel L, Bulzacka E, Aouizerate B, Berna F, Capdevielle D, D'Amato T, Denizot H, Dubertret C, Dubreucq J, Faget C, Gabayet F, Llorca PM, Mallet J, Misdrahi D, Passerieux C, Rey R, Richieri R, Schandrin A, Urbach M, Vidailhet P, Costagliola D, Fond G; FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group.

J Psychiatr Res. 2017 Nov;94:62-69. doi: 10.1016/j.jpsychires.2017.06.008. Epub 2017 Jun 20.

PMID:
28668717
50.

Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study.

Caniglia EC, Cain LE, Sabin CA, Robins JM, Logan R, Abgrall S, Mugavero MJ, Hernández-Díaz S, Meyer L, Seng R, Drozd DR, Seage GR 3rd, Bonnet F, Dabis F, Moore RD, Reiss P, van Sighem A, Mathews WC, Del Amo J, Moreno S, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Napravnik S, Jose S, Phillips A, Justice AC, Tate JP, Gill J, Pacheco A, Veloso VG, Bucher HC, Egger M, Furrer H, Porter K, Touloumi G, Crane H, Miro JM, Sterne JA, Costagliola D, Saag M, Hernán MA; HIV-CAUSAL Collaboration; Centers for AIDS Research Network of Integrated Clinical Systems.

Lancet HIV. 2017 Jun;4(6):e251-e259. doi: 10.1016/S2352-3018(17)30043-7. Epub 2017 Apr 11.

Supplemental Content

Loading ...
Support Center